FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer After Treatment Failure
The FDA granted accelerated approval to a subcutaneous amivantamab therapy that shrank tumors in 42% of patients with recurrent or metastatic head and neck cancer.
Summary
The FDA has granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum-based chemotherapy and immunotherapy. In an open-label trial of 102 patients, 42% responded, meaning their tumors shrank or disappeared. Of those responders, 56% maintained the response for six months or longer. Currently approved options achieve response rates of about 20% or less. It is the first drug approved in 10 years for this patient group after prior platinum chemotherapy. The approval rests on surrogate endpoints, so confirmatory trials must still show real survival or quality-of-life benefit. Warnings include lung inflammation, skin and eye toxicity, infusion-type reactions, and harm to an unborn baby. It is not indicated for HPV-associated oropharyngeal cancer.
Detailed Summary
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer that often returns or spreads after first-line treatment. Once platinum-based chemotherapy and immunotherapy stop working, patients have had very few options, and outcomes have remained poor. That unmet need is why the FDA's new decision matters to oncology and to anyone following cancer research.
On November 5, 2026, the FDA granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), made by Janssen Biotech, for adults with recurrent or metastatic HNSCC that progressed on or after platinum chemotherapy and immunotherapy. In an open-label, multicenter trial of 102 patients, the overall response rate was 42%, meaning tumors shrank or vanished. Among responders, 56% had responses lasting six months or longer. Existing therapies produce response rates of roughly 20% or less. The agency described this as the first approval in 10 years for recurrent or metastatic HNSCC after prior platinum-based chemotherapy, and the drug received Breakthrough Therapy designation.
Accelerated approval is built on surrogate or intermediate endpoints, here overall response rate and duration of response. These measures suggest activity but do not prove patients live longer or feel better. For that reason the FDA is requiring confirmatory studies to verify and describe clinical benefit.
Practically, this gives oncologists and patients a new option at a stage where choices are scarce. Safety warnings matter: hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, dermatologic reactions, ocular toxicity, and harm to an unborn baby. The drug is not indicated for HPV-associated oropharyngeal squamous cell carcinoma, so tumor type and prior treatment history determine eligibility.
Caveats are important. The trial was open-label and single-arm in design as described, with no randomized comparison reported here, and the 42% figure is compared with historical benchmarks. Survival data are not yet available. Readers should view this as a promising but provisional advance and consult the full prescribing information and trial publications.
Key Findings
- FDA granted accelerated approval to Rybrevant Faspro for recurrent or metastatic HNSCC after platinum chemotherapy and immunotherapy.
- Overall response rate was 42% in 102 patients, versus about 20% or less for currently approved therapies.
- 56% of responders maintained their response for six months or longer.
- Approval is based on surrogate endpoints; confirmatory trials must verify real clinical benefit.
- Warnings include lung inflammation, skin and eye toxicity, hypersensitivity reactions, and fetal harm.
Methodology
This is an official FDA news release summarizing a regulatory decision and an open-label, multicenter trial of 102 patients. The source is highly credible for approval facts, but it offers limited trial detail and no peer-reviewed data. Evidence is based on response rate and duration, not survival.
Study Limitations
Accelerated approval does not confirm improved survival or quality of life, and the single-arm trial lacks a randomized control. Verify details such as dosing, patient selection, and adverse event rates in the full prescribing information and published trial results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
